Radiol Cardiothorac Imaging 2020 Oct 29;2(5):e200102. Epub 2020 Oct 29.
Department of Diagnostic and Interventional Radiology, University Medical Center Goettingen, Robert-Koch-Strasse 40, 37075 Goettingen, Germany (J.U., O.A.B., J.L.); Section of Interventional Radiology, Yale School of Medicine, New Haven, Conn (J.U.); Department of Radiology, Antwerp University Hospital, Antwerp, Belgium (R.S.); Department of Radiology, Holy Heart Hospital, Lier, Belgium (R.S.); Department of Radiological, Oncological and Pathological Sciences, Sapienza University of Rome, Rome, Italy (M.F.); Department of Radiology, Center for Medical Imaging, University Medical Center Groningen, Groningen, the Netherlands (R.V.); Radiology Department, University Hospital Basel, Basel, Switzerland (J.B.); German Cardiovascular Research Center (DZHK), Partner site Goettingen, Germany (J.L.); and Department of Diagnostic and Interventional Radiology, University of Leipzig-Heart Centre, Leipzig, Germany (M.G.).
Purpose: To assess current use and acute safety profiles of gadolinium-based contrast agents (GBCAs) in cardiac MRI given recent suspensions of GBCA approval.
Materials And Methods: Patients were retrospectively included from the multinational multicenter European Society of Cardiovascular Radiology (ESCR) MR/CT Registry collected between January 2013 and October 2019. GBCA-associated acute adverse events (AAEs) were classified as mild (self-limiting), moderate (pronounced AAE requiring medical management), and severe (life threatening). Read More